» Articles » PMID: 37082497

Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation

Overview
Journal Cureus
Date 2023 Apr 21
PMID 37082497
Authors
Affiliations
Soon will be listed here.
Abstract

With an increasing global incidence in children younger than the age of five, respiratory syncytial virus (RSV) is one of the most common viral respiratory infections worldwide. Despite the increasing number of cases among infants and young children, RSV can infect any age group; however, some individuals are more high risk than others. Premature infants, young children, elderly, and immunocompromised individuals are the most likely to suffer a more severe presentation of RSV in comparison to healthy adults. RSV is transmitted through respiratory droplets via direct contact with an infected individual or with contaminated surfaces. The viral genome of RSV consists of 11 proteins. Out of these 11, two proteins allow for the attachment of the virus to the respiratory epithelial cells and fusion with host cells. Upon fusion, the viral material transfers to the host cell, where viral replication occurs. It is important to acknowledge that an individual is considered infectious and can transmit the virus even before the symptomatic presentation of RSV begins. As long as the individual is shedding the virus, he or she is considered infectious. The length of viral shedding also differs depending on the severity of the infection, who is infected, and the underlying immune status of an individual. Currently, there is no definitive treatment for RSV; however, supportive therapy is considered the mainstay treatment. Some pharmaceutical treatments such as ribavirin have been FDA-approved; however, the administration is typically limited to children and infants. Palivizumab is also administered as an immune prophylaxis; however, both therapies are constantly at the end of a cost-effective debate due to their extensively expensive nature and questionable adverse effect profiles. Supportive therapy includes hydration, supplemental oxygen, and mechanical ventilation in hospitalized cases; however, most RSV cases can be treated as outpatient cases. Prevention techniques such as hand washing and maintaining social distancing are imperative to minimize the transmission of the virus as much as remotely possible.

Citing Articles

Deciphering respiratory viral infections by harnessing organ-on-chip technology to explore the gut-lung axis.

Koceva H, Amiratashani M, Akbarimoghaddam P, Hoffmann B, Zhurgenbayeva G, Gresnigt M Open Biol. 2025; 15(3):240231.

PMID: 40037530 PMC: 11879621. DOI: 10.1098/rsob.240231.


Call to include breastfeeding as a synergistic approach to vaccines for prevention of respiratory syncytial virus disease.

Fischer L, Okanmelu E, Theurich M Int Breastfeed J. 2025; 20(1):12.

PMID: 40033309 PMC: 11874759. DOI: 10.1186/s13006-025-00705-9.


Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines.

Anastassopoulou C, Medic S, Ferous S, Boufidou F, Tsakris A Vaccines (Basel). 2025; 13(2).

PMID: 40006644 PMC: 11860200. DOI: 10.3390/vaccines13020097.


Molecular epidemiology and phylogenetic analysis of human respiratory syncytial virus type B in Riyadh, Saudi Arabia.

Aljowaie R, Farrag M, Abalkhail T, Aziz I, Almuqrin A, Alkubaisi N Virus Genes. 2025; .

PMID: 39966224 DOI: 10.1007/s11262-025-02143-5.


Respiratory syncytial virus: A review of current basic and clinical knowledge.

Al-Leimon O, Shihadeh H, Yousef A, Khraim A, Siwwad R Qatar Med J. 2025; 2024(4):56.

PMID: 39931346 PMC: 11809256. DOI: 10.5339/qmj.2024.56.


References
1.
Vanover D, Smith D, Blanchard E, Alonas E, Kirschman J, Lifland A . RSV glycoprotein and genomic RNA dynamics reveal filament assembly prior to the plasma membrane. Nat Commun. 2017; 8(1):667. PMC: 5610308. DOI: 10.1038/s41467-017-00732-z. View

2.
McL Rixon H, Brown G, Aitken J, McDonald T, Graham S, Sugrue R . The small hydrophobic (SH) protein accumulates within lipid-raft structures of the Golgi complex during respiratory syncytial virus infection. J Gen Virol. 2004; 85(Pt 5):1153-1165. DOI: 10.1099/vir.0.19769-0. View

3.
Falsey A, Walsh E . Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000; 13(3):371-84. PMC: 88938. DOI: 10.1128/CMR.13.3.371. View

4.
Tran T, Castagne N, Dubosclard V, Noinville S, Koch E, Moudjou M . The respiratory syncytial virus M2-1 protein forms tetramers and interacts with RNA and P in a competitive manner. J Virol. 2009; 83(13):6363-74. PMC: 2698528. DOI: 10.1128/JVI.00335-09. View

5.
Piedimonte G . RSV infections: State of the art. Cleve Clin J Med. 2015; 82(11 Suppl 1):S13-8. DOI: 10.3949/ccjm.82.s1.03. View